187 related articles for article (PubMed ID: 32710448)
1. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
[TBL] [Abstract][Full Text] [Related]
2. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
3. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
[TBL] [Abstract][Full Text] [Related]
4. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry.
Courant M; Orazio S; Monnereau A; Preterre J; Combe C; Rigothier C
Nephrol Dial Transplant; 2021 Feb; 36(3):482-490. PubMed ID: 31773154
[TBL] [Abstract][Full Text] [Related]
5. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
6. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Dimopoulos MA; Delimpasi S; Katodritou E; Vassou A; Kyrtsonis MC; Repousis P; Kartasis Z; Parcharidou A; Michael M; Michalis E; Gika D; Symeonidis A; Pouli A; Konstantopoulos K; Terpos E; Kastritis E
Ann Oncol; 2014 Jan; 25(1):195-200. PubMed ID: 24356630
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
[TBL] [Abstract][Full Text] [Related]
8. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
[TBL] [Abstract][Full Text] [Related]
9. Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.
de Vries JC; Oortgiesen B; Hemmelder MH; van Roon E; Kibbelaar RE; Veeger N; Hoogendoorn M
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28278719
[TBL] [Abstract][Full Text] [Related]
10. Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement.
Park S; Han B; Kim K; Kim SJ; Jang JH; Kim WS; Jung CW
Anticancer Res; 2014 Aug; 34(8):4299-306. PubMed ID: 25075062
[TBL] [Abstract][Full Text] [Related]
11. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
[TBL] [Abstract][Full Text] [Related]
12. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
PLoS One; 2014; 9(7):e101819. PubMed ID: 25003848
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A
Blood; 2011 Nov; 118(22):5759-66. PubMed ID: 21951682
[TBL] [Abstract][Full Text] [Related]
14. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Leung N; Rajkumar SV; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kapoor P; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust S; Kyle RA; Gertz MA; Kumar SK
Blood Cancer J; 2015 Mar; 5(3):e296. PubMed ID: 25794132
[TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].
Zhu W; Lu J; Lu J; Hou J; Huang X; Chen W
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):741-4. PubMed ID: 26080844
[TBL] [Abstract][Full Text] [Related]
16. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
17. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
An N; Li X; Shen M; Chen SL; Huang ZX
Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
[No Abstract] [Full Text] [Related]
18. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]